The goal of the main clinical research study is to learn if treatment with a chimeric antigen receptor (CAR) T-cell therapy called lisocabtagene maraleucel (liso-cel) can help to prevent recurrence of large B-cell cell lymphoma in patients who have achieved complete response (CR) after standard first-line therapy but have tested positive for lymphoma DNA. CAR T therapy is a type of treatment that uses your own immune cells to fight your cancer. The safety of this treatment will also be studied.
R-CHOP (cyclophosphamide, doxorubicin, vincristine sulfate, and prednisone)
DA-EPOCH-R
Polatuzumab-R-CHP 8. Achieved complete metabolic response by Lugano criteria4 at the end of treatment response evaluation after first line treatment
Absolute neutrophil count (ANC) ≥1.0 × 109 /L*
Having radiologically confirmed relapsed/refractory disease.
Have not recovered from non-hematological AEs due to prior first line therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
Known central nervous system lymphoma or leptomeningeal disease.
Adequately treated localized non-melanoma skin cancer without evidence of disease.